UVLRX-THERAPEUTICS
11.11.2015 08:04:15 CET | Business Wire | Press release
UVLrx Therapeutics ™ is pleased to present its intravenous light treatment system at the 5th Annual Pro-Aging Europe Congress , a four-day event highlighting medical therapies that reduce, slow down and even reverse the aging process. Beginning on November 19th , this year’s Congress will attract hundreds of the world’s leading anti-aging and aesthetics physicians.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151110007124/en/
Following the company’s recent CE Mark clearance for the UVLrx Station™ Model UVL1500, UVLrx Therapeutics™ will highlight the clinically-proven benefits of light wavelengths utilized by the UVLrx Treatment System. The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical issues. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body.
Among UVLrx Therapeutics Model UVL1500’s eight indications for use in the EU, the UVLrx™ Treatment System significantly reduces inflammation, the root cause of accelerated aging. It also significantly reduces pain and accelerates post surgical healing, two critical factors associated with many aesthetic procedures.
“We are excited to share our technology at the Congress this year and demonstrate in person how we can contribute to patient care within the field of aesthetics and aging,” says Michael Harter, CEO and president of UVLrx™. “By exhibiting at this event, under the supervision of Dr. Thierry Hertoghe , we have the opportunity to treat the world’s leading anti-aging physicians, which will help them understand firsthand UVLrx’s potential within this growing medical field.”
Ultraviolet Blood Irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion in drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, please visit http://uvlrx.com/ and http://bit.ly/1RLN2zb . Be sure to attend UVLrx’s Therapeutic Workshop at the Pro-Aging Congress featuring Chief Scientist Ryan Maloney on Friday, November 20th from 7:00 p.m. to 9:30 p.m.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx
Therapeutics is dedicated to evidence-based medicine in the field of
light therapy and offers the first intravenous, concurrent delivery of
ultraviolet-A (UVA) and multiple visible light wavelengths for treating
a variety of medical issues. In addition to two Nobel Prizes and
NASA-backed research, hundreds of international clinical trials have
verified the health benefits of UV and other wavelengths of light
utilized in the UVLrx™ Treatment System. For more information, please
visit www.uvlrx.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151110007124/en/
Contact:
Press:
Crier Communications
JP Lincoln, 310-274-1072 ext. 201
jp@crierpr.com
or
Business:
UVLrx
Therapeutics
Rowland Hanson
Rowland@UVLrx.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Andersen Consulting styrker sine kompetencer med tilføjelsen af Lukkap2.4.2026 16:31:00 CEST | Pressemeddelelse
Andersen Consulting tilføjer samarbejdspartneren Lukkap, et konsulenthus med fokus på oplevelsesdrevne kompetencer, der er tilpasset kundernes skiftende behov inden for transformation af medarbejdere, kunder og det digitale område. Lukkap, der blev stiftet i 2009 og har hovedsæde i Spanien, leverer integrerede løsninger, der hjælper organisationer med at transformere, hvordan de betjener kunder, engagerer medarbejdere og frigør værdi gennem adfærdsindsigt og dataanalyse. Virksomhedens tværfaglige tilgang spænder over nytænkning af kunderejsen, effektive programmer for medarbejderoplevelser, talent- og ledelsesudvikling, prædiktiv analyse samt omfattende outplacement- og transitionsydelser. Lukkap arbejder på tværs af sektorer — herunder sundhedsvæsen, medicinalindustri, forbrugsgoder, detailhandel, finans og bankvæsen — for at opbygge menneskecentrerede strategier, der skaber målbare forretningsresultater. "Ved at kombinere vores erfaringsdrevne metode med Andersen Consultings globale
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press release
Low AI fluency, uneven adoption, and marginal productivity gains are limiting enterprise-scale impact According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA® Fiber2.4.2026 15:00:00 CEST | Press release
Agreement with Texhong Advances Sustainable Fiber Applications The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang,
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press release
New identity reflects expanded vision to help CIOs “See Clearly. Spend Better.” Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom